http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
A356 알루미늄 합금의 파단 충격에너지에 대한 수축공결함의 영향
황성철 ( Seong Chul Hwang ),곽시영 ( Si Young Kwak ) 한국주조공학회 2014 한국주조공학회지 Vol.34 No.1
Internal defects, such as shrinkage during casting, cause stress concentrations and initiate cracking. Therefore, it is important to understand the effects of internal defects on the mechanical properties including the impact behavior. This study evaluates the effects of internal casting defects on the impact performance of A356 Al-alloy castings. The internal shrinkage defects in the casting impact specimen are scanned using an industrial Computed Tomography (CT) scanner, and drop impact tests are performed with varing impact velocities on the A356 casting aluminium specimen (10 mm × 10 mm section area) in order to locate the fracture energy under an impact load. The specimens with defects with a diameter less than 0.35 mm exhibit equivalent fracture impact energies of approximately 32 J and those with a 1.7 mm diameter defect reduced the fracture impact energy by 35%.
방사선 조사후 손상된 백서 폐조직에서의 Thioredoxin Peroxidase의 발현
정성철 ( Seong Cheoll Cheong ),박준성 ( Joon Seong Park ),박지원 ( Jee Won Park ),이선민 ( Sun Min Lee ),박광주 ( Kwang Joo Park ),황성철 ( Sung Chul Hwang ),이이형 ( Yi Hyeong Lee ),한명호 ( Myung Ho Hahn ),오영택 ( Young Taek 대한결핵 및 호흡기학회 1999 Tuberculosis and Respiratory Diseases Vol.47 No.5
구조응력기반 마스터 S-N 선도를 이용한 노치를 가지는 Al 7075 시편의 피로수명예측
곽시영(Si Young Kwak),황성철(Seong Chul Hwang),홍정균(Jeong Kyun Hong) 대한기계학회 2018 大韓機械學會論文集A Vol.42 No.2
본 논문에서는 임의의 응력 집중 계수를 갖는 일반 노치 구조물에 대한 마스터 S-N 선도를 이용한 피로 수명 예측 방법을 제안한다. 먼저 미국의 바텔 연구소에서 수행한 알루미늄 7075 노치 시험편(Kt = 1.5, 2, 4, 5)에 대한 피로 수명 데이터를 이용하여 구조응력을 계산하고 이에 기초한 마스터 S-N 선도를 작성하였다. 그 후 작성된 마스터 선도에서 유도된 예측 값과 Kt 3의 노치 시편에 대해 새롭게 실시한 피로 시험 결과를 비교하였다. 이러한 과정을 통해 결과적으로 구조응력 기반 마스터 S-N 선도의 피로 수명 예측의 정확성과 유용성을 검증하였다. This paper proposes the possibility of fatigue life estimation using the master S-N curve of a general notched structure with arbitrary stress concentration factor. Firstly, the structure stress was computed from the fatigue data that had been generated by Battelle Institute for Al 7075-T6 notched specimens (Kt=1.5, 2, 4, 5), and a master S-N curve based on the structural stress was drawn up. Secondly, a novel fatigue test was conducted for a notched specimen (Kt=3) and the result of this test was compared to the predictive value derived from the master S-N curve. From these processes, it was possible to validate the accuracy and usefulness of fatigue life estimation using master S-N curve.
인체 폐암조직에서 Phospholipase C-$\gamma1$의 활성화 단백, AHNAK의 발현양상
오윤정,박준성,최소연,정성철,이선민,황성철,이이형,한명호,이기범,류한영,하만준,배윤수,이서구,Oh, Yoon-Jung,Park, Chun-Seong,Choi, So-Yeon,Cheong, Seong-Cheoll,Lee, Sun-Min,Hwang, Sung-Chul,Lee, Yi-Hyeong,Hahn, Myung-Ho,Lee, Kyi-Beom,Ryu, Han 대한결핵및호흡기학회 1999 Tuberculosis and Respiratory Diseases Vol.47 No.3
배경: Phospholipase C(PLC)는 세포의 성장, 분화, 변형(transformation)과 관련된 세포내 신호 전달과정에 중추적인 역할을 하는 효소이다. 이들 중 PLC-$\gamma$는 tyrosine kinase의 인산화에 의해 주로 활성화되는 데, 최근에 phosphatidic acid(PA), phosphatidy-linositol 3, 4, 5-trisphosphate($PIP_3$), tau 단백에 의한 활성화 기전이 밝혀진 바 있다. 특히 tau 단백은 bovine brain에서 arachidonic acid와 함께 PLC-$\gamma$를 활성화시키는 것으로 알려져 PLC-$\gamma$와 $PLA_2$ 사이의 cross-talk이 이루어질 가능성이 제시되고 있다. 최근 보고에 의하면 tau 단백과 같은 기전으로 PLC-${\gamma}1$ 활성화시키는 단백이 bovine lung에서 발견되었고, 이 활성화 단백을 정제 및 클론하여 AHNAK 단백임이 확인된 바 있다. 또한 PLC-${\gamma}1$이 유방암, 대장암, 위암 등에서 증가되어 있어 발암 과정과 연관되어 있음이 보고되어 왔으나 PLC-${\gamma}1$의 활성화 단백인 AHNAK 단백에 대해서는 질병과 관련되어 연구된 것이 아직 없는 실정이며 저자 등은 폐암 조직과 정상 폐조직에서 AHNAK 단백의 발현 양상을 연구하여 폐암의 발암과정에 AHNAK 단백이 관여함을 밝히고자 하였다. 대상 및 방법: 아주대학교 병원에 내원하여 폐암으로 수술을 받은 환자의 폐암 조직과 동일 환자의 정상 폐조직에서 AHNAK 단백의 발현양상을 western blot 분석과 면역조직화학적 염색방법을 통하여 조사하였다. 결과: 14예의 편평상피암 세포조직 중 8예 (57.1 %)와 14예의 선암 세포조직 모두에서 정상 대조군에 비해 AHNAK 단백의 발현이 증가하였고, 70 kDa~200kDa의 여러가지 분자량을 가지는 띠모양으로 나타났다. 면역조직화학적 염색에서도 정상 폐조직보다 폐암 조직내에서 강한 발색반응을 보였다. 결론: PLC-${\gamma}1$의 활성화 단백인 AHNAK 단백이 폐암 조직에서 정상 조직보다 과발현된 것은, AHNAK 단백이 PLC-${\gamma}1$을 활성화시켜 폐암의 발생 기전에 관여할 수 있음을 뒷받침한다고 하겠다. Background: Phospholipase C(PLC) plays a central role in cellular signal transduction and is important in cellular growth, differentiation and transformation. There are currently ten known mammalian isozymes of PLC reported to this date. Hydrolysis of phosphatidylinositol 4,5-bisphosphate($PIP_2$) by PLC produces two important second messengers, inositol 1,4,5-trisphosphate($IP_3$) and diacylglycerol. PLC-${\gamma}1$, previously, was known to be activated mainly through growth factor receptor tyrosine kinase. Other mechanisms of activating PLC-yl have been reported such as activation through tau protein in the presence of arachidonic acid in bovine brain and activation by $IP_3$, phosphatidic acid, etc. Very recently, another PLC-${\gamma}1$ activator protein such as tau has been found in bovine lung tissue, which now is considered to be AHNAK protein. But there has been no report concerning AHNAK and its associated disease to this date. In this study, we examined the expression of the PLC-${\gamma}1$ activator, AHNAK, in lung cancer specimens and their paired normal. Methods: From surgically resected human lung cancer tissues taken from twenty-eight patients and their paired normal counterparts, we evaluated expression level of AHNAK protein using immunoblot analysis of total tissue extract Immunohistochemical stain was performed with primary antibody against AHNAK protein. Results: Twenty-two among twenty-eight lung cancer tissues showed overexpression of AHNAK protein (eight of fourteen squamous cell lung cancers, all of fourteen adenocarcinomas). The resulting bands were multiple ranging from 70 to 200 kDa in molecular weight and each band was indistinct and formed a smear, reflecting mobility shift mainly due to proteolysis during extraction process. On immunohistochemistry, lung cancer tissues showed a very heavy, dense staining with anti-AHNAK protein antibody as compared to the surrounding normal lung tissue, coresponding well with the results of the western blot Conclusion: The overexpression of PLC-${\gamma}1$ activator protein, AHNAK in lung cancer may provide evidence that the AHNAK protein and PLC-${\gamma}1$ act in concerted manner in carcinogenesis.
비소세포폐암의 림프절 병기 결정에서 Coincidence PET의 역할
이선민 ( Sun Min Lee ),최영화 ( Young Hwa Choi ),정성철 ( Seong Cheoll Cheong ),오윤정 ( Yoon Jung Oh ),박광주 ( Kwang Joo Park ),황성철 ( Sung Chul Hwang ),이이형 ( Yi Hyeong Lee ),박찬희 ( Chan H. Park ),한명호 ( Myung Ho Hah 대한결핵 및 호흡기학회 1999 Tuberculosis and Respiratory Diseases Vol.47 No.5
다양한 악성 종양에서의 말초혈액조혈 모세포이식을 통한 고용량 항암치료
김현수,구성현,최소연,조요한,지석배,박준성,박희붕,황성철,유희석,전미선,조용관,김효철 대한조혈모세포이식학회 1996 대한조혈모세포이식학회지 Vol.1 No.1
High dose chemotherapy with autologous stem cell transplantation is a new therapeutic strategy for various malignancy, especially leukemia, lymphoma, breast cancer. Recently, increasing number of trials has been done in solid tumors responsive to conventional chemotherapy using high dose chemotherapy and autologous peripheral blood stem cell transplantation. At Ajou University Hospital, between August 1995 and September 1996, 60 patients received high dose chemotherapy with peripheral blood stem cell transplantation, which in cluded 20 stomach cancers, 16 breast cancers, 15 lymphomas, 4 lung cancers, 3 ovarian cancers, 1 cervix cancer and 1 cancer of unknown primary cancer. Median age of patients was 44 years(range, 19 to 66), and male to female ratio was 0.7:1. The median time to recovery to neutrophil count more than 0.5x109/L was 11 days, and platelet count more than 20x109/L and 50x109/L was 13 and 17 days. With high dose chemotherapy in 41 patients who had relapsed or refractory disease, the complete remission was achieved in 34%(14/41) of patients and overall response rate was 83%(34/41). There was high response rate in spite of various tumor and various status of disease. In with stomach cancer and breast cancer who were given HDCT with adjuvant treatment aim, high dose chemotherapy was well tolerated with minimal non-hematogic toxicity and morbidity. During high dose chemotherapy, there was three transplantation related death, 2 sepsis and 1 veno-occlusive disease. Our experience suggest is well tolerated procedure which confers that high dose chemotherapy with peripheral blood transplantation will be a promising treatment modality for the relapsed and refractory tumors, as well as for patients with high risk for relapse following curative surgical resection.